This Blood Vessel Was Grown in a Lab With Real Human Cells
The FDA recently approved a bioengineered blood vessel, which becomes part of a patient’s body over time. It’s designed to ...
Humacyte and Pluristyx enhance partnership for diabetes treatment
DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology firm specializing in bioengineered human tissues with a current market capitalization of $580 million, and Pluristyx, Inc., a provider of ...
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas ...
Pluristyx has developed a clinical-grade manufacturing process for using a licensed Mad7 gene editing technology to block Human Leukocyte Antigen (HLA) markers expression. Humacyte is optimizing a ...
Humacyte, Inc: Humacyte and Pluristyx Announce Gene Editing Partnership to Support ...
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue ...